Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties.
Ontology highlight
ABSTRACT: Raloxifene is an FDA approved agent used to treat bone loss and decrease fracture risk. In clinical trials and animal studies, raloxifene reduces fracture risk and improves bone mechanical properties, but the mechanisms of action remain unclear because these benefits occur largely independent of changes to bone mass. Using a novel experimental approach, machined bone beams, both from mature male canine and human male donors, were depleted of living cells and then exposed to raloxifene ex vivo. Our data show that ex vivo exposure of non-viable bone to raloxifene improves intrinsic toughness, both in canine and human cortical bone beams tested by 4-point bending. These effects are cell-independent and appear to be mediated by an increase in matrix bound water, assessed using basic gravimetri
SUBMITTER: Gallant MA
PROVIDER: S-EPMC3955028 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA